Zurück zur Hauptseite

Unternehmen auf Beobachtungsliste setzen

thyssenkrupp nucera AG & Co. KGaA

ISIN: DE000NCA0001

WKN: NCA000

Über

Snapshot Unternehmen

Neu: Benachrichtigung aktivieren

Aktuelle Nachrichten per Alarm empfangem

Neu: KI-Factsheet

Coming soon: Zusammenfassung der Unternehmensnachricht durch KI/p>

thyssenkrupp nucera AG & Co. KGaA · ISIN: DE000NCA0001 · Newswire (Unternehmen)

Land: Deutschland · Primärmarkt: Deutschland · EQS NID: 2032301

Levermann Score

18 November 2024 18:01PM

thyssenkrupp nucera recorded strong sales growth and slightly better-than-expected earnings in Q4 and FY 2023/24; project execution well on track

EQS-News: thyssenkrupp nucera AG & Co. KGaA / Key word(s): Preliminary Results
thyssenkrupp nucera recorded strong sales growth and slightly better-than-expected earnings in Q4 and FY 2023/24; project execution well on track

18.11.2024 / 18:01 CET/CEST
The issuer is solely responsible for the content of this announcement.

TRADING STATEMENT: thyssenkrupp nucera recorded strong sales growth and slightly better-than-expected earnings in Q4 and FY 2023/24; project execution well on track

Q4 2023/24: Strong performance in the last quarter with positive order intake momentum, strongly growing alkaline water electrolysis (AWE) sales and resilient profitability

Growing order intake driven by Chlor-Alkali (CA) service business; AWE order intake on prior year’s level
Strong year-on-year sales growth due to AWE business; AWE sales doubled in Q4 and thereby reached a new all-time high, reflecting significant progress of projects under execution; CA sales roughly on par with previous year
EBIT below prior year, but slightly better than expected; EBIT decline due to planned ramp-up costs and lower gross margin in line with higher AWE sales share, partly offset by strong margins in CA business and cost containment

FY 2023/24:

Order intake slightly above prior year’s level, largely driven by the AWE project with Stegra (H2 Green Steel) in Sweden; CA order intake fell from the previous year’s record high, which was supported by the large OxyChem project in the US
Group sales guidance of 820mn € to 900mn € reached as well as AWE sales target of 500mn € to 550mn €; both sales figures came in roughly in the middle of the range
- Strong sales increase mostly driven by the dynamic sales growth in the AWE business following ongoing execution of projects, especially in Saudi Arabia and Sweden
- CA sales slightly above prior year’s level
EBIT slightly better than originally expected (guidance: negative EBIT figure in mid double-digit mn € range)
- Significant year-on-year EBIT decline mainly due to the planned organizational ramp-up and AWE capacity build-up, higher R&D expenditures as well as the increased share of AWE sales, which is currently still accompanied by lower gross margins
- Successful CA business delivered healthy profit margins and thereby supported the expansion towards green hydrogen

All statements reported herein are preliminary and unaudited. Full financial disclosure for Q4/FY 2023/24 will be published as planned on 17 December 2024 at 07:00 am CET.

18.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	thyssenkrupp nucera AG & Co. KGaA
	Freie-Vogel-Str. 385 a
	44269 Dortmund
	Germany
Phone:	+49 231-22972-7100
E-mail:	info@thyssenkrupp-nucera.com
Internet:	www.thyssenkrupp-nucera.com
ISIN:	DE000NCA0001
WKN:	NCA000
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2032301


End of News	EQS News Service

2032301 18.11.2024 CET/CEST

Research & Analysen